Policy / Politics Tanks, guns and face-painting The uncanny festivities of the US Army's 250th anniversary, celebrated on Donald Trump's birthday. by Tina Nguyen Jun 14, 2025, 9:36 PM EDT Link Facebook Threads 0 Comments / 0 New AFP via Getty Images
In what's become a bit of a Decoder tradition, I spoke with Google CEO Sundar Pichai in person after I/O. The conference this year was all about AI, particularly a slew of actual AI products, not just models and capabilities. To Sundar, this marks the beginning of a new era for search and the web overall. So I had to ask: what happens to the web when AI tools and eventually agents do most of the browsing for us? It was a very Decoder conversation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
According to Gallup, 71% of middle-income Americans are invested in the stock market, and they've watched their fortunes rise and fall repeatedly during the volatile period since President Donald Trump announced his trade tariffs on April 2. But as the official start of summer approaches, those who resisted the urge to panic-sell during the frightening declines have largely seen their discipline pay off. Check Out: Read Next: It's impossible to gauge what the average middle-class investor might have gained or lost because the concept is a construct, regardless of the investor's socioeconomic class. Even if it were possible to put a dollar amount on the mean middle-class earner's stock investments, that would ignore critical variables like that investor's: Type, size and number of stock or fund holdings Portfolio makeup Portfolio diversity Degree of leverage from options trading or margin borrowing Trade frequency Fees and expenses Discover More: For context on just how differently two otherwise similar middle-class investors can perform, consider that Warner Bros Discovery Inc. (WBD) cratered on April 2 and retained a 24% overall loss through June 10. Conversely, Palantir Technologies Inc. (PLTR) has been one of the top performers in the post-tariff era, adding most of its 74% year-to-date gains since April 2. Two middle-class stock pickers with identical incomes and backgrounds who rolled the anti-diversification dice by purchasing identical amounts in either stock on April 1 would have had radically different outcomes between then and mid-June. A more reliable metric might be the major indices that so many middle-class households invest in through their 401(k)s, IRAs, index funds and ETFs. Between April 2 and June 10: The S&P 500, the benchmark index for the U.S. stock market, gained 6.16%. The Dow Jones Industrial Average, which tracks the blue chips, gained 1.31%. The tech-heavy and more volatile Nasdaq gained 11.57%. The FTSE All Cap Index, which includes much of the global stock market with 10,000 small-, mid- and large-cap companies in both developed and emerging markets, gained 7.22%. The average among all four is 6.57%, which is roughly what typical middle-class earners might have gained since April 2 if they followed the conventional advice of diversifying their portfolios with a blend of blue chips, growth stocks and foreign equities, and holding their positions regardless of market behavior. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Clever Ways To Save Money That Actually Work in 2025 7 Tax Loopholes the Rich Use To Pay Less and Build More Wealth This article originally appeared on How Much the Average Middle-Class American Has Gained in the Stock Market Since Trump Announced His Tariffs
Yahoo
34 minutes ago
- Yahoo
NHS faces paying more for US drugs to avoid future Trump tariffs
Britain faces paying more for US drugs as part of a deal to avoid future tariffs from Donald Trump. The NHS will review drug pricing to take into account the 'concerns of the president', according to documents released after a trade agreement was signed earlier this year. White House sources said it expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of corporate America. A Westminster source said: 'There's an understanding that we would look at the drug pricing issue in the concerns of the president.' The disclosure is likely to increase concerns about American interference in the British health service, which has long been regarded as a flashpoint in trade talks. It comes after Rachel Reeves announced a record £29 billion investment in the NHS in last week's spending review. The Chancellor's plans will drive spending on the health service up towards 50 per cent of all taxpayer expenditure by the mid-2030s, according to economists at the Resolution Foundation. The Telegraph has also learnt that under the terms of the trade deal with America, the UK has agreed to take fewer Chinese drugs, in a clause similar to the 'veto' given to Mr Trump over Chinese investment in Britain. The White House has asked the UK for assurances that steel and pharmaceutical products exported to the US do not originate in China, amid fears the deal could be used to 'circumvent' Mr Trump's punishing tariffs on Beijing. Mr Trump is enraged by how much more America pays for drugs compared with other countries and considers it to be the same issue as he has raised on defence spending. Just as the US president has heaped pressure on European nations to increase the GDP share they allocate to defence, he thinks they should spend more on drug development. An industry source said: 'The way we've been thinking about it and many in the administration have been thinking about it, it's more like the model in Nato, where countries contribute some share of their GDP.' Britain and the US 'intend to promptly negotiate significantly preferential treatment outcomes on pharmaceuticals and pharmaceutical ingredients', the trade deal reads. Pharmaceutical companies are also pushing for reductions in the revenue sales rebates they pay to the NHS under the voluntary scheme for branded medicines pricing, access and growth (VPAG) – a mechanism that the UK uses to make sure the NHS does not overpay. Last week, Albert Bourla, Pfizer's chief executive, said non-US countries were 'free-riding' and called for a US government-led push to make other nations increase their proportionate spend on innovative medicines. He said White House officials were discussing drug prices in trade negotiations with other countries. 'We represent in UK 0.3pc of their GDP per capita. That's how much they spend on medicine. So yes, they can increase prices,' Mr Bourla said. Industry sources said there was no indication yet on what the White House would consider to be a fair level of spending. Whatever the benchmark, Britain will face one of the biggest step-ups. UK expenditure on new innovative medicines is just 0.28pc of its GDP, roughly a third of America's proportionate spending of 0.78pc of its GDP. Even among other G7 nations, the UK is an anomaly. Germany spends 0.4pc of its GDP while Italy spends 0.5pc. Most large pharmaceutical companies generate between half and three quarters of their profits in the US, despite the fact that America typically makes up less than a fifth of their sales. This is because drug prices outside of the US can cost as little as 30pc of what Americans pay. Yet, pharmaceutical companies rely on higher US prices to fund drug research and development, which the rest of the world benefits from. A month ago, Mr Trump signed an executive order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients', which hit out at 'global freeloading' on drug pricing. It stated that 'Americans should not be forced to subsidise low-cost prescription drugs and biologics in other developed countries, and face overcharges for the same products in the United States' and ordered his commerce secretary to 'consider all necessary action regarding the export of pharmaceutical drugs or precursor material that may be fuelling the global price discrimination'. Trung Huynh, the head of pharma analysis at UBS, said: 'The crux of this issue is Trump thinks that the US is subsidising the rest of the world with drug prices. 'The president has said he wants to equalise pricing between the US and ex-US. And the way he wants to do it is not necessarily to bring down US prices all the way to where ex-US prices are, but he wants to use trade and tariffs as a pressure point to get countries to increase their prices. 'If he can offset some of the price by increasing prices higher ex-US, then the prices in America don't have to go down so much.' Mr Huynh added: 'It's going to be very hard for him to do. Because [in the UK deal] it hinges on the NHS, which we know has got zero money.' Under VPAG, pharmaceutical companies hand back at least 23pc of their revenue from sales of branded medicines back to the NHS, worth £3bn in the past financial year. The industry is pushing for this clawback to be cut to 10pc, which would mean the NHS would have to spend around 1.54bn more on the same medicines on an annual basis. The Government has already committed to reviewing the scheme, a decision which is understood to pre-date US trade negotiations. A government spokesman said: 'This Government is clear that we will only ever sign trade agreements that align with the UK's national interests and to suggest otherwise would be misleading. 'The UK has well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply.'
Time Business News
34 minutes ago
- Time Business News
TeamDesk Integration with OpenAI- A Guide to Unlocking AI-Powered Efficiency
In today's fast-paced digital world, businesses are constantly looking for ways to optimize workflows and improve decision-making. TeamDesk, a powerful online database system, enables businesses to organize and manage data effectively. However, integrating TeamDesk with OpenAI can take data management to a whole new level by introducing AI-powered automation, insights, and intelligent decision-making. This article explores the benefits of integrating TeamDesk with OpenAI, potential use cases, and step-by-step instructions on how to set up this integration for enhanced business performance. Benefits of Integrating TeamDesk with OpenAI By linking TeamDesk with OpenAI, businesses can unlock numerous advantages, such as: Automated Data Processing: AI models can analyze vast amounts of data stored in TeamDesk, extract insights, and generate reports automatically. Natural Language Processing (NLP): OpenAI's NLP capabilities allow businesses to interpret unstructured text data, classify customer queries, and provide sentiment analysis. Enhanced Customer Support: AI-powered chatbots can interact with customers using data stored in TeamDesk, ensuring accurate and contextual responses. Predictive Analytics: Businesses can forecast trends, customer behaviors, and sales patterns using OpenAI's predictive capabilities. Document Generation: AI can generate contracts, reports, and summaries based on data from TeamDesk. Task Automation: AI-driven automation reduces manual effort in processing and updating records within TeamDesk. Use Cases for TeamDesk and OpenAI Integration 1. AI-Powered Data Analysis Organizations can use OpenAI to analyze large datasets stored in TeamDesk and derive meaningful insights. For example, an HR department can process employee feedback and extract key sentiment trends. 2. Automated Report Generation Instead of manually compiling reports, OpenAI can generate executive summaries, sales reports, and performance evaluations based on structured data from TeamDesk. 3. Customer Support Automation Integrating OpenAI with TeamDesk allows businesses to deploy AI chatbots that fetch real-time data from the database, offering customers accurate and quick responses. 4. Email Automation OpenAI can draft and personalize email responses based on customer interactions stored in TeamDesk, ensuring better engagement and efficiency. 5. Fraud Detection & Risk Management With AI's pattern recognition capabilities, businesses can identify unusual activities and flag potential fraudulent transactions in their database. Steps to Integrate TeamDesk with OpenAI To successfully integrate TeamDesk with OpenAI, follow these steps: Step 1: Set Up API Access for TeamDesk TeamDesk provides API access to interact with external applications. To enable API access: Log into TeamDesk. Navigate to Setup > Integrations > API Access. Generate an API key to allow external applications (such as OpenAI) to interact with TeamDesk. Note down the API endpoint for retrieving and updating records. Step 2: Obtain OpenAI API Key To use OpenAI's capabilities: Visit OpenAI's website and sign up for an API key. Choose the AI model you want to use (GPT-4, GPT-3.5, or fine-tuned models). Save the API key securely for later use. Step 3: Connect TeamDesk and OpenAI Using a Middleware Since TeamDesk and OpenAI use different APIs, middleware such as Zapier, Make (formerly Integromat), or custom scripts can help connect them. Using Zapier: Create a Zap and select TeamDesk as the trigger. Choose an event (e.g., 'New Record Created' or 'Updated Record'). Select OpenAI as the action app and define the task (e.g., 'Summarize Text' or 'Generate Email Response'). Map the fields between TeamDesk and OpenAI. Activate the Zap to automate the workflow. Step 4: Develop a Custom Integration (Optional) For more control, businesses can develop a custom integration using Python or JavaScript. Example: Python Script for TeamDesk & OpenAI Integration import requests def get_teamdesk_data(): teamdesk_url = ' headers = {'Authorization': 'Bearer YOUR_TEAMDESK_API_KEY'} response = headers=headers) return def send_to_openai(prompt): openai_url = ' headers = {'Authorization': 'Bearer YOUR_OPENAI_API_KEY', 'Content-Type': 'application/json'} data = {'model': 'gpt-4', 'prompt': prompt, 'max_tokens': 200} response = headers=headers, json=data) return data = get_teamdesk_data() prompt = 'Summarize this customer feedback: ' + str(data) result = send_to_openai(prompt) print(result['choices'][0]['text']) Step 5: Test and Deploy After setting up the integration: Test the workflow to ensure seamless data transfer. Optimize the AI model's responses for accuracy. Deploy the integration and monitor performance. Conclusion Integrating TeamDesk with OpenAI enables businesses to leverage AI for automating workflows, enhancing customer service, and driving data-driven decision-making. Whether through no-code platforms like Zapier or custom-built Python scripts, this integration can transform business operations. By combining the power of structured databases with AI-driven insights, organizations can boost efficiency, reduce manual tasks, and enhance productivity. Ready to take your data management to the next level? Start integrating TeamDesk with OpenAI today! TIME BUSINESS NEWS
